Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 8/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 1/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.84 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.84 |
| ▸ | FLT1 | P17948 | 1/20 | 0.84 |
| ▸ | FLT4 | P35916 | 1/20 | 0.84 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435811 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14KDRRIPK2ACVR1B | |
| SCHEMBL29504112 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14KDRRIPK2ACVR1B | |
| SCHEMBL14086523 | 0.93 | TGFBR1 (0.87) | TGFBR1MAPK14KDRRIPK2ACVR1B | |
| SCHEMBL22170124 | 0.93 | TGFBR1 (0.86) | TGFBR1MAPK14KDRRIPK2ACVR1B | |
| SCHEMBL14086529 | 0.92 | TGFBR1 (0.85) | TGFBR1MAPK14KDRRIPK2ACVR1B | |
| SCHEMBL14086499 | 0.92 | TGFBR1 (0.85) | TGFBR1MAPK14KDRRIPK2ACVR1B | |
| SCHEMBL4875304 | 0.91 | TGFBR1 (1.00) | TGFBR1MAPK14KDRRIPK2ACVR1B | |
| SCHEMBL30373643 | 0.91 | TGFBR1 (1.00) | TGFBR1MAPK14KDRRIPK2ACVR1B | |
| SCHEMBL14086514 | 0.90 | TGFBR1 (0.82) | TGFBR1MAPK14KDRRIPK2ACVR1B | |
| SCHEMBL14086516 | 0.90 | TGFBR1 (0.81) | TGFBR1MAPK14KDRRIPK2ACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371664-B2 | Medium for direct differentiation of pluripotent stem cell-derived mesenchymal stem cell, method for preparing mesenchymal stem cell by using same, and mesenchymal stem cell prepared thereby | CHA BIOTECH CO., LTD. (KR) | 2025-07-29 | — | — | US | claimed |
| US-20250188420-A1 | MATURING AGENT HAVING BOTH OF ALK5 INHIBITORY ACTIVITY AND CDK8/19 INHIBITORY ACTIVITY | Orizuru Therapeutics, Inc. (JP) | 2025-06-12 | — | — | US | claimed |
| EP-4516894-A1 | MATURING AGENT HAVING BOTH OF ALK5 INHIBITORY ACTIVITY AND CDK8/19 INHIBITORY ACTIVITY | Orizuru Therapeutics, Inc. (JP) | 2025-03-05 | — | — | EP | claimed |
| WO-2023210578-A1 | MATURING AGENT HAVING BOTH OF ALK5 INHIBITORY ACTIVITY AND CDK8/19 INHIBITORY ACTIVITY | オリヅルセラピューティクス株式会社 | 2023-11-02 | — | — | WO | claimed |
| US-20210340498-A1 | MEDIUM FOR DIRECT DIFFERENTIATION OF PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL, METHOD FOR PREPARING MESENCHYMAL STEM CELL BY USING SAME, AND MESENCHYMAL STEM CELL PREPARED THEREBY | CHA BIOTECH CO., LTD. (KR) | 2021-11-04 | — | — | US | claimed |
| EP-3848455-A1 | MEDIUM FOR DIRECT DIFFERENTIATION OF PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL, METHOD FOR PREPARING MESENCHYMAL STEM CELL BY USING SAME, AND MESENCHYMAL STEM CELL PREPARED THEREBY | CHA Biotech Co., Ltd. (KR) | 2021-07-14 | — | — | EP | claimed |
| CN-112996903-A | Culture medium for directly differentiating pluripotent stem cell-derived mesenchymal stem cells, method for preparing mesenchymal stem cells by using culture medium and mesenchymal stem cells prepared by using culture medium | 车比奥泰有限公司 | 2021-06-18 | — | — | CN | claimed |
| US-8871744-B2 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partyers, LLC (US) | 2014-10-28 | — | — | US | claimed |
| US-12618049-B2 | Reprogramming methods and cell culture platforms | FATE THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4715043-A1 | METHOD FOR PRODUCING NEURAL CREST CELLS | Kyoto University (JP) | 2026-03-25 | — | — | EP | disclosed |
| US-20260035664-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12516288-B2 | Method for producing enteric neural precursors | KYOTO UNIVERSITY (JP) | 2026-01-06 | — | — | US | disclosed |
| US-20260000735-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2010144678-A2 | GENERATION OF VASCULARIZED HUMAN HEART TISSUE AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100267141-A1 | CHEMICAL APPROACHES FOR GENERATION OF INDUCED PLURIPOTENT STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-10-21 | — | — | US | disclosed |
| WO-2010077955-A1 | GENERATION AND MAINTENANCE OF STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2009117439-A2 | COMBINED CHEMICAL AND GENETIC APPROACHES FOR GENERATION OF INDUCED PLURIPOTENT STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-09-24 | — | — | WO | disclosed |
| US-7407958-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2008-08-05 | — | — | US | disclosed |
| US-7407958-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2008-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD4, CD22 | TGFBR1 443/4885MAPK14 1645/4885KDR 52/4885 |
| US-12618049-B2 | Reprogramming methods and cell culture platforms | WNT3A, FGF2, MEF2D | TGFBR1 14/4885MAPK14 149/4885KDR 944/4885 |
| US-20260000735-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | IAPP, PNLIP, PPARD | TGFBR1 977/4885MAPK14 1957/4885KDR 4039/4885 |
| US-20260035664-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD14, HGF | TGFBR1 94/4885MAPK14 1087/4885KDR 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.